Metformin in Postmenopausal Women With Metabolic Syndrome

Effects of Metformin on Cardiovascular Risk Factors in Postmenopausal Women With Metabolic Syndrome

The purpose of this study is to determine the effects of metformin on cardiovascular risk factors in postmenopausal women with metabolic syndrome.

Inclusion Criteria:

• Postmenopausal women aged 45-60 years with metabolic syndrome according to The American Heart Association and The National Heart, Lung, and Blood Institute

Exclusion Criteria:

• Previous cardiovascular diseases
• Contraindicated to metformin: serum creatinine >1.4 mg/dL, liver disease, alcoholism, congestive heart failure, chronic hypoxic lung disease, prior history of lactic acidosis
• Previous administration of metformin, other hypoglycemic drugs, lipid-lowering drugs, sex steroids, antiplatelet drugs within 3 months before enrollment
• Fasting blood sugar ≥ 200 mg/dL or HbA1c >8%
• Serum triglyceride ≥500 mg/dL
• Abnormal EKG